P/B
21,1
Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
$11.1B
Market Cap • 10/23/2026
2011
(15 years)
Founded
2007
(19 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
8,6
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
20,6
EPS
—
Market Cap
Market Cap
11,1B
EV
10,6B
EV/Revenue
8,2
EV/EBITDA
-32,9
EV/EBIT
-32,8
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,3%
Total Yield
-0,3%
Payout
0%
Retained Earnings
-2,2B
Profitability
Gross Margin
91,5%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
38,2%
Capex/Revenue
0,7%
Capex/D&A
564,9%
Capex/OCF
-4,3%
SBC/OCF
—
% PPE
1,4%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Op. Income 5Y
6,7%
CAGR Net Income 5Y
7%
CAGR EPS 5Y
-4,1%
CAGR OCF 5Y
0,5%
Leverage
N.D./EBITDA
1,5
Debt/Equity
0%
Current Ratio
3,2
Quick Ratio
2,8
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!